The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
Nutrition & Biosciences Division of DuPont de Nemours, Inc.
Advising IFF, a global leader in flavors and fragrances, on its merger with DuPont’s Nutrition & Biosciences Division, creating a clear global leader in the specialty ingredients sector
Allergan Generics
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
Gallaher Group plc
Advised Gallaher Group plc, the world’s fifth largest tobacco company, on a recommended cash offer from Japan Tobacco Inc
Kelda Group plc
Advised Kelda Group plc, a leading provider of water and waste water services in the UK, on a recommended cash offer from a consortium of international infrastructure investors
Tesco plc’s Thailand and Malaysia businesses
Advised Tesco plc, a leading UK retailer, on the sale of its Thailand and Malaysia businesses to Charoen Pokphand Group, the Thai conglomerate
Frutarom
Advised IFF, a leading innovator of specialty ingredients, on its acquisition of Frutarom, creating a global leader in Taste, Scent and Nutrition
Lion Nathan
Advised Lion Nathan, a leading brewery in Australia, on the sale of its remaining 54% stake to Kirin Holdings, a leading beverage company in Japan
Assets owned by GlaxoSmithKline plc
Advised GlaxoSmithKline plc, the UK listed international pharmaceutical and consumer healthcare company, on the divestment of Horlicks and other consumer healthcare nutrition brands to Unilever plc, and on the merger of GSK Consumer Healthcare Limited with Hindustan Unilever Limited
Global collaboration agreement with Genmab A/S
Advised AbbVie, Inc, an NYSE-listed global biopharmaceutical company, on a broad collaboration with Genmab A/S, a leading Danish-listed biotechnology company, to jointly develop and commercialise three next-generation bispecific antibody programs
Australian Unity Funds Management
Advised Australian Unity Funds Management on its successful defence of Australian Unity Healthcare Property Trust, in response to four unsolicited offers from a consortium comprised of NorthWest Healthcare Properties REIT and Singaporean sovereign wealth fund, GIC
Lucozade & Ribena brands (owned by GSK)
Advised GlaxoSmithKline, the UK listed international pharmaceutical and consumer company, on the sale of its nutritional drinks brands Lucozade and Ribena to Suntory Beverage & Food Ltd
Yakult
Advised Danone, a leading global food & beverage company, on renewing its strategic partnership with Yakult, a global leader in probiotic beverages, as well as the sale of part of its stake in Yakult
Martabe gold and silver mine
Advised EMR Capital, a specialist resources private equity manager, on the sale of the Martabe gold and silver mine to United Tractors
LIXIL VIVA
Advising Arcland Sakamoto, a leading owner and operator of large home centers, on the acquisition of LIXIL VIVA, a leading owner and operator of large home centers and a listed subsidiary of LIXIL Group, a leading Japanese manufacturer of building and housing materials
7-Eleven, Inc.
Advised the special committee of 7-Eleven, Inc. in connection with its evaluation of an unsolicited tender offer commenced by Seven-Eleven Japan Co., Ltd
COOEC Fluor Heavy Industries Co., Ltd.
Advised Fluor Corporation on its $489 million investment for a 49% interest in a joint venture with Offshore Oil Engineering Co., Ltd. (COOEC) to own, operate and manage the Zhuhai Fabrication Yard in China’s Guangdong province
Minnesota Rubber and Plastics
Facilitated the sale of KKR’s portfolio company Minnesota Rubber and Plastics, a leading provider of materials science-based elastomer and thermoplastic solutions, to Trelleborg
Megapolis Distribution
Advised Japan Tobacco Inc in connection with the acquisition of a minority stake in Megapolis Distribution B.V., Russia’s leading tobacco distributor
Portfolio of Towers from PLDT
Advising edotco Group, the leading pan-Asian telecom tower infrastructure company, on the acquisition of 2,973 towers from PLDT, one of the largest telecommunication service providers in the Philippines, through a sale and leaseback transaction
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
ITX (Mobile Phone Retailing Business)
Advised Japan Industrial Partners, a leading private equity firm in Japan, on the acquisition of mobile phone retailing business from ITX, a mobile phones marketer and distributor in Japan
Diabetes-related patent estate and royalty stream of Astellas Pharma subsidiary, Prosidion
Advised Royalty Pharma, a leading acquiror of biopharmaceutical royalty interests, on the acquisition of the DPP-IV patent estate and associated royalty stream of Astellas Pharma subsidiary, Prosidion
Lion’s stake in Warrnambool Cheese and Butter Factory Company
Advised Lion (an Australian subsidiary of Kirin), on the sale of its strategic stake in Warrnambool Cheese and Butter Factory to Canadian-based Saputo, under its all cash takeover offer
Little World Beverages
Advised Lion on the acquisition of Little World Beverages, Australia’s largest listed brewer and one of the country’s leading players in the Craft beer segment
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories